Ameriplan Corporation – Trademark Portfolio
Entity Type: 03
Ameriplan Corporation holds 32 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 19 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AMERIPLAN HEALTH and A AMERIPLAN HEALTH. The owner is based in Plano, TX.
5700 Democracy Drive, Suite 1000
Plano, TX 750247126
Showing of trademarks Trademarks
Trademark Classifications
Ameriplan Corporation's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Ameriplan Corporation have?
Ameriplan Corporation has 32 U.S. trademarks filed with the USPTO. Of these, 2 registered, 8 abandoned, 22 cancelled.
What trademark classes does Ameriplan Corporation file in?
Ameriplan Corporation files trademarks across 3 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are Ameriplan Corporation's most well-known trademarks?
Ameriplan Corporation's registered trademark portfolio includes well-known marks such as AMERIPLAN HEALTH and A AMERIPLAN HEALTH. These are among 2 currently registered trademarks in the portfolio.
What is Ameriplan Corporation's trademark registration success rate?
Ameriplan Corporation has a 6% trademark registration rate, with 2 out of 32 resolved applications resulting in successful registration. Currently, 0 applications are pending review.